Efficacy and safety of rituximab biosimilar in refractory lupus
Aims To characterise patients with refractory SLE receiving rituximab biosimilar (CT-P10) and to explore short-term efficacy and safety associated with rituximab biosimilar use.Methods We retrospectively analysed data from the medical records of patients with refractory SLE who received CT-P10 in Ra...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-12-01
|
| Series: | Lupus Science and Medicine |
| Online Access: | https://lupus.bmj.com/content/7/1/e000442.full |